The Marshall Lambert Symposium Contributions and Road Log

Road log of the Upper Cretaceous and lower Tertiary geology and paleontology of extreme southwestern North Dakota. Field trip sponsored by the Pioneer Trails Museum, June 19–20, 1993, Bowman, North Dakota. Published by the North Dakota Geological Society

Modeling of GERDA Phase II data

The GERmanium Detector Array (GERDA) experiment at the Gran Sasso underground laboratory (LNGS) of INFN is searching for neutrinoless double-beta ($0\nu\beta\beta$) decay of $^{76}$Ge. The technological challenge of GERDA is to operate in a "background-free" regime in the region of interest (ROI) after analysis cuts for the full 100$\,$kg$\cdot$yr target exposure of the experiment. A careful modeling and decomposition of the full-range energy spectrum is essential to predict the shape and composition of events in the ROI around $Q_{\beta\beta}$ for the $0\nu\beta\beta$ search, to extract a precise measurement of the half-life of the double-beta decay mode with neutrinos ($2\nu\beta\beta$) and in order to identify the location of residual impurities. The latter will permit future experiments to build strategies in order to further lower the background and achieve even better sensitivities. In this article the background decomposition prior to analysis cuts is presented for GERDA Phase II. The background model fit yields a flat spectrum in the ROI with a background index (BI) of $16.04^{+0.78}_{-0.85} \cdot 10^{-3}\,$cts/(kg$\cdot$keV$\cdot$yr) for the enriched BEGe data set and $14.68^{+0.47}_{-0.52} \cdot 10^{-3}\,$cts/(kg$\cdot$keV$\cdot$yr) for the enriched coaxial data set. These values are similar to the one of Gerda Phase I despite a much larger number of detectors and hence radioactive hardware components

Modeling of GERDA Phase II data

The GERmanium Detector Array (Gerda) experiment at the Gran Sasso underground laboratory (LNGS) of INFN is searching for neutrinoless double-beta (0νββ) decay of 76Ge. The technological challenge of Gerda is to operate in a “background-free” regime in the region of interest (ROI) after analysis cuts for the full 100 kg·yr target exposure of the experiment. A careful modeling and decomposition of the full-range energy spectrum is essential to predict the shape and composition of events in the ROI around Qββ for the 0νββ search, to extract a precise measurement of the half-life of the double-beta decay mode with neutrinos (2νββ) and in order to identify the location of residual impurities. The latter will permit future experiments to build strategies in order to further lower the background and achieve even better sensitivities. In this article the background decomposition prior to analysis cuts is presented for Gerda Phase II. The background model fit yields a flat spectrum in the ROI with a background index (BI) of 16.04+0.78−0.85⋅10−3 cts/(keV·kg·yr) for the enriched BEGe data set and 14.68+0.47−0.52⋅10−3 cts/(keV·kg·yr) for the enriched coaxial data set. These values are similar to the one of Phase I despite a much larger number of detectors and hence radioactive hardware components

Lithostratigraphy, tephrochronology, and rare earth element geochemistry of fossils at the classical Pleistocene fossil lake area, South Central Oregon

A B S T R A C T One of the most famous fossiliferous Pleistocene sites in the Pacific Northwest is Fossil Lake, Oregon. Until recently, fossil collections from the area were not stratigraphically controlled, owing to the lack of a detailed stratigraphic and chronologic framework. Our field studies reveal at least nine exposed thin rhythmic fining-upward depositional packages, most separated by disconformities. Analysis of interbedded tephras reveals that the Rye Patch Dam (∼646 ka), Dibekulewe (∼610 ka), Tulelake T64 (∼95 ka), Marble Bluff (47 ka), and Trego Hot Springs (23.2 ka) tephra layers are present in the section, indicating deposition from more than ∼646 ka to less than 23 ka, which includes both the late Irvingtonian and Rancholabrean North American land mammal ages, a much longer time span than previously believed. Bones analyzed from eight of the defined units have distinctly different rare earth element (REE) signatures. Fossils obtain REE during early diagenesis, and signatures are probably closely related to lake water compositions. REE signatures in fossils from lower packages suggest uptake from neutral pH waters. In contrast, REE signatures become increasingly heavy REE-enriched up-section, with positive Ce anomalies in the upper units. REE signatures in fossils from the upper units are very similar to waters from modern alkaline lakes, such as Lake Abert, Oregon, suggesting diagenetic uptake in increasingly alkaline and saline waters. These REE changes suggest increasing aridity up-section, a contention reinforced by the habitat preferences of the terrestrial vertebrates preserved

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo

Background: Cardiovascular (CV) disease is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Furthermore, patients with T2DM and acute coronary syndrome (ACS) have a particularly high risk of CV events. The glucagonlike peptide 1 receptor agonist, lixisenatide, improves glycemia, but its effects on CV events have not been thoroughly evaluated. Methods: ELIXA (www.clinicaltrials.gov no. NCT01147250) is a randomized, double-blind, placebo-controlled, parallelgroup, multicenter study of lixisenatide in patients with T2DM and a recent ACS event. The primary aim is to evaluate the effects of lixisenatide on CV morbidity and mortality in a population at high CV risk. The primary efficacy end point is a composite of time to CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. Data are systematically collected for safety outcomes, including hypoglycemia, pancreatitis, and malignancy. Results: Enrollment began in July 2010 and ended in August 2013; 6,068 patients from 49 countries were randomized. Of these, 69% are men and 75% are white; at baseline, the mean ± SD age was 60.3 ± 9.7 years, body mass index was 30.2 ± 5.7 kg/m2, and duration of T2DM was 9.3±8.2 years. The qualifying ACS wasamyocardial infarctionin83% and unstableangina in 17%. The study will continue until the positive adjudication of the protocol-specified number of primary CV events. Conclusion: ELIXA will be the first trial to report the safety and efficacy of a glucagon-like peptide 1 receptor agonist in people with T2DM and high CV event risk. © 2015 Elsevier Inc. All rights reserved